Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus.
Sign up today and learn more about Codagenix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Codagenix Stock
Codagenix is a developer of live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. Its vaccines utilize Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain.
Chief Medical Officer
Chief Business Officer
Member Board Of Director
Co-Founder & President, Chief Scientific Officer
Co-Founder & Senior Scientific Advisor
Chief Strategy Officer
EVP of Animal Health
Bruce E. Taillon
Co-Founder & Chief Executive Officer
J. Robert Coleman